Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Eisai’s Fycompa Cuts Tonic-Clonic Seizure Frequency by 76.5%
December 9, 2014
- Adcetris Significantly Extends PFS in Post-Transplant Hodgkin lymphoma Patients: Takeda
December 9, 2014
- Abilify Maintena Approved for Use in Acutely Relapsed Adults with Schizophrenia in the US: Otsuka, Lundbeck
December 9, 2014
- April-September Sales Drop 21.5% for Major Long-Listed Products
December 8, 2014
- Daiichi Sankyo to Harness Ties with Cardiologists in Lixiana Promotion
December 8, 2014
- Pfizer Japan Launches CML Drug Bosulif
December 8, 2014
- Zenyaku Kogyo to Initiate Preclinical Study for Nucleic Acid Medicine for Psoriasis as Early as Next Year
December 8, 2014
- COPD Drug Ultibro Launched in UK
December 8, 2014
- CareNet, EP-PharmaLine to Jointly Provide Online, Phone Detailing Services
December 8, 2014
- Nipro Sets Up New Sales Firm in Malaysia
December 8, 2014
- Nippon Chemiphar to Set Up Plant in Vietnam, Operation Launch Slated in 2018
December 5, 2014
- First-Line Xalkori Shows Superiority to Chemotherapy in ALK-Positive NSCLC: Pfizer
December 5, 2014
- Chiome Bioscience Succeeds in Producing Antibody to Ebola
December 5, 2014
- Asahi Kasei Pharma Licenses Teribone to South Korea’s Dong-A ST
December 5, 2014
- M3 Poised to More than Double Revenue from Clinical Trial Services
December 5, 2014
- Safety Confirmed in Preliminary Results from PI Study of Preventive AIDS Vaccine: Dnavec
December 4, 2014
- Astellas, Janssen to End JAK Inhibitor Licensing Agreement
December 3, 2014
- Nippon Shinyaku’s Selexipag Filed for European Approval
December 3, 2014
- Otsuka to Buy US Firm Avanir Pharmaceuticals to Fully Enter Neurology Market
December 3, 2014
- Takata Seiyaku Obtains Marketing Authorization Rights for Antihistamine Polaramine from MSD
December 3, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…